A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V)

Journal of Diabetes Science and Technology

Volumn 8, Issue 1, 2014, Pages 132-141

  Pai, Vikas ^a   Paneerselvam, A ^b   Mukhopadhyay, Satinath ^c   Bhansali, Anil ^d   Kamath, Dinesh ^e   Shankar, V ^f   Gambhire, Dhiraj ^g   Jani, Rajendrakumar H ^g   Joshi, Shashank ^h   Patel, Pankaj ^g  

^a Pai Clinic   (India)

^b Aruna Diabetes Centre   (India)

^c INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^d POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^e Sudeep Diabetes Care Centre   (India)

^f Standard Laboratory and Polyclinic   (India)

^g ZYDUS RESEARCH CENTRE   (India)

^h Dr Joshi's Imaging Clinic Mumbai   (India)

Author keywords

Hypertriglyceridemia; Pioglitazone; Saroglitazar; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; PIOGLITAZONE; SAROGLITAZAR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ASTHENIA; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC DYSLIPIDEMIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; GASTRITIS; GLUCOSE BLOOD LEVEL; HEMATEMESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THORAX PAIN; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84900559988     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296813518680     Document Type: Article

References (27)

1. Goldfine AB, Fonseca V. Management of diabetes mellitus in patients with cardiovascular disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2010;121:2447-2449.
2. Harris MI, Entmacher PS. Mortality from diabetes. In: Harris MI, Hamman RF, eds. Diabetes in America. Washington, DC: Government Printing Office; 1985: 1-48.
3. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple RISK Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
4. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59:8-13.
5. Savage P. Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Ann Intern Med. 1996;124(1):123-126.
6. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463-524.
7. Solano MDP, Goldberg RB. Management of diabetic dyslipidemia. Endocrine Metab Clin N Am. 2005;34:1-25.
8. Gerstein HC, Riddle MC, Kendall DM, et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk In Diabetes (ACCORD) trial. Am J Cardiol. 2007;99(12A):34i-43i.
9. Heller SR. A summary of the ADVANCE trial. Diabetes Care. 2009;32(2):357-361.
10. Sever PS, Dahlof B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288:2998-3007.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
13. Ridker PM, Danielson E, Fonseca FA, et al JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
14. Baigent C, Keech A, Kearney PM, et al Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
15. Alla VM, Kaushik M, Mooss A. Targeting residual risk: the rationale for the use of non HDL cholesterol. Southern Med J. 2010;103(5):434-437.
16. Miller M, Stone NJ, Ballantyne C, et al. Triglyceride and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292-2333.
17. Grundy SM, Cleeman JI, Merz CN, et al National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program adult treatment panel III guidelines Circulation. 2004;110:227-239.
18. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart. 2008;94:706-714.
19. Jani RH, Kansagra K, Jain M, Patel H. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominant PPARα agonist and moderate γ agonist activity in healthy human subjects. Clin Drug Investig. 2013;33:809-816.
20. Robert RH, Lincoff AM, Sunder M, Michael R, Cathy C, Matthias H. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009;374:126-135.
21. Prescribing information. Indications and usage for Tricor. Available at: http://www.drugs.com/pro/tricor.html. Accessed September 2, 2013.
22. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:1547-1553.
23. Balaji V. Efficacy and safety of pioglitazone in type 2 diabetes in the Indian patients: results of an observational study. Indian J Endocrinol Metab. 2013;17(4):709-715.
24. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
25. Nissen SE, Wolski K. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294:2581-2586.
26. Gerstein HC, Miller ME, Byington RP, et al. Effect of intensive glucose lowering in type 2 diabetes. N Eng J Med. 2008;358:2545-2549.
27. Patel A, MacMohan S, Chalmers J, et al. Intensive blood glucose control and vascular outcome in patients with type 2 diabetes. N Eng J Med. 2008;358:2560-2572.